Axonopathy in an α-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated α-synuclein
about
c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's diseaseAdult hippocampal neurogenesis in Parkinson's disease: impact on neuronal survival and plasticityParkinson's disease genes VPS35 and EIF4G1 interact genetically and converge on α-synucleinNext-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.Late-stage α-synuclein accumulation in TNWT-61 mouse model of Parkinson's disease detected by diffusion kurtosis imaging.Novel AAV-based rat model of forebrain synucleinopathy shows extensive pathologies and progressive loss of cholinergic interneuronsReducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models.Overexpression of the calpain-specific inhibitor calpastatin reduces human alpha-Synuclein processing, aggregation and synaptic impairment in [A30P]αSyn transgenic mice.Cerebrolysin™ efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure.Cross dimerization of amyloid-β and αsynuclein proteins in aqueous environment: a molecular dynamics simulations study.Environmental neurotoxic challenge of conditional alpha-synuclein transgenic mice predicts a dopaminergic olfactory-striatal interplay in early PD.Mitochondrial Dysfunction and α-Synuclein Synaptic Pathology in Parkinson's Disease: Who's on First?Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease.α-Synuclein interferes with the ESCRT-III complex contributing to the pathogenesis of Lewy body disease.Reducing Endogenous α-Synuclein Mitigates the Degeneration of Selective Neuronal Populations in an Alzheimer's Disease Transgenic Mouse Model.Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy.The utility of α-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature.Gene therapy targeting mitochondrial pathway in Parkinson's disease.Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivoThe Search for a Peripheral Biopsy Indicator of α-Synuclein Pathology for Parkinson Disease.Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5--implications for dementia with Lewy bodies.α-synuclein conformational antibodies fused to penetratin are effective in models of Lewy body disease.Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy.Dopaminergic lesioning impairs adult hippocampal neurogenesis by distinct modification of α-synuclein.Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleinopathies.A de novo compound targeting α-synuclein improves deficits in models of Parkinson's disease.The Challenge of the Pathogenesis of Parkinson's Disease: Is Autoimmunity the Culprit?The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's diseaseReduced Cytosolic Calcium as an Early Decisive Cellular State in Parkinson's Disease and Synucleinopathies
P2860
Q24318974-38FB5A9F-6839-4825-89C1-20F57ACED3FDQ26862840-91B96F34-BE28-4D53-B062-1EFD3A365201Q28117589-25C4FB92-2979-422D-835E-615CCEBC1628Q30578913-E69ABA78-C906-40CC-B736-A480910D907DQ31032932-585E238D-E0DB-45A5-A112-72E11D8484E8Q33856698-9008ACF3-DA42-4A02-8897-98A698F565EDQ33865366-F4BAA95F-ABE0-45EF-8347-66F878C99B68Q33947949-15D072FC-BF99-4D3A-A29A-1D2A7EDAD3E9Q34006701-70429884-E40C-4D7A-9D1A-9399C6D3CE1DQ34165988-8C9412B9-935F-441F-979C-6ED08E276E35Q35073958-42D2B001-FEBE-417E-8C86-34F7C4B2B2D1Q35412397-F485279D-6177-4ABC-A726-F3BD192D5954Q35510197-84C61F0B-0DA4-4730-BE7A-138A8968E899Q36608855-B4E47971-9FD3-47BB-8593-8404A726838AQ37127867-3979571A-51B8-4B86-B66A-BCA32811CEBFQ37586721-6BB243E9-2D2A-4E5B-85DD-61287162ACC9Q38575114-2884EF7B-83A5-47FE-8E63-4840A0694D53Q38957332-57607DB2-BC81-458E-8ABC-EE5D9F91FDFEQ38966914-E343ADC0-1A85-4BF6-B66C-623F67F39042Q39077485-E7C62006-334D-43CE-BE06-4A55AFED74CBQ40150743-3391A6F8-17F7-4764-99B2-19223D9DCF92Q41117719-4C26C476-DDCB-4E24-A2CD-9FB4B1261288Q46124320-3E18C008-3C9E-4124-9F58-E30F395C8E60Q46657177-6E53100A-D646-4DEC-AA1D-5D945946A103Q47563994-D163C340-9B9C-4FD3-91DC-3844828EE3B5Q48493933-C0DE102A-3ABA-49F9-B5EB-B23D672C382EQ57490878-00F7F940-1349-45B9-8523-0D50FED53E7FQ58577817-BDD39A4E-F215-4075-B185-6BE9CC34BFC8Q59128094-0BFA87B8-C8AF-4D16-B9D8-012C3E43F991
P2860
Axonopathy in an α-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated α-synuclein
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Axonopathy in an α-synuclein t ...... terminal-truncated α-synuclein
@ast
Axonopathy in an α-synuclein t ...... terminal-truncated α-synuclein
@en
type
label
Axonopathy in an α-synuclein t ...... terminal-truncated α-synuclein
@ast
Axonopathy in an α-synuclein t ...... terminal-truncated α-synuclein
@en
prefLabel
Axonopathy in an α-synuclein t ...... terminal-truncated α-synuclein
@ast
Axonopathy in an α-synuclein t ...... terminal-truncated α-synuclein
@en
P2093
P2860
P50
P1476
Axonopathy in an α-synuclein t ...... terminal-truncated α-synuclein
@en
P2093
Christina Patrick
Dale Schenk
Dora Games
Majid Ghassemiam
Margarita Trejo
Peter Seubert
Robin Barbour
P2860
P304
P356
10.1016/J.AJPATH.2012.11.018
P407
P577
2013-01-09T00:00:00Z